Recruits Lab places drug safety and pharmacovigilance professionals across case processing, signal detection, aggregate reports, risk management, and QPPV leadership. We know the difference between a Safety Scientist who can defend a signal and one who has only processed ICSRs. Average hire time: 14 days.
Pharmacovigilance is the single most regulated function inside any biopharmaceutical company. Every approved product requires continuous monitoring of adverse events, periodic aggregate safety reporting, signal detection, and risk minimization. A weak PV function is an inspection finding waiting to happen and a launch delay risk that no commercial plan survives.
Recruits Lab is a specialist pharmacovigilance recruiting firm working with venture-backed biotechs preparing for first commercial launch, mid-cap pharma scaling their global safety database, and CROs growing case processing capacity. We have placed Safety Scientists, Aggregate Report Authors, Signal Detection Leads, Risk Management Plan owners, EU and UK Qualified Persons for Pharmacovigilance, and Vice Presidents of Drug Safety.
PV hiring is constrained by three structural realities. First, the experienced PV physician pool is shallow and aging. Second, ICH E2E, GVP Module IX, and 21 CFR 314.80 fluency cannot be self-taught quickly. Third, regulators expect a defensible safety organization to exist on the day of approval, not six months later. Hiring late is the most common reason launches slip.
Our recruiters source from the actual pool. We map from established safety organizations at Pfizer, Merck, Bristol-Myers Squibb, Sanofi, GSK, AstraZeneca, Novartis, and Roche, plus the safety practices at top CROs including IQVIA, Parexel, Labcorp, ICON, and Syneos. We know who has launch experience, who has FDA and EMA inspection history, and who is ready to move from a large pharma to an emerging biotech.
Recruits Lab works on a flat monthly subscription for ongoing PV team build-out or a success-based contingency model for one-off QPPV and VP-level searches. Every placement carries a 90-day replacement guarantee. We do not work on retainer.
Why this market is hard to recruit for. And how we solve each one.
Safety physicians with case review and signal evaluation experience are a small population. We maintain ongoing relationships with most of the active U.S. and EU pool and know who is ready to move.
ICH E2E, GVP IX, FAERS, EudraVigilance, and PSUR/PBRER fluency cannot be picked up in a 30-day onboarding. We screen for direct hands-on regulatory work, not LinkedIn keywords.
Hiring a Director of PV three months before approval is too late. We work with sponsors 9-12 months out to build the safety function on a defensible timeline.
EU and UK QPPV roles require residency and 24/7 availability. The compliant pool is small. We screen for residency and language fluency on day one.
A great case processor at a CRO is not always the right Safety Scientist at a sponsor. We calibrate on autonomy, signal ownership, and stakeholder skill.
PSUR, PBRER, DSUR, and PADER cadence drives the size of the team. We model headcount to product portfolio before agreeing the search.
The repeatable system behind our 14-day average hire time.
90-minute call covering product portfolio, regulatory commitments, vendor model, inspection history, and the actual case volume that drives headcount.
Fresh map of 80-150 PV professionals from competitor sponsors, CRO safety practices, and consulting firms. We do not scrape a database.
Messages written by recruiters who can speak credibly about GVP Module IX, signal detection methodology, and recent FDA safety actions. Response rates run 35-50 percent.
Finalists arrive with regulatory experience flags, inspection history, system fluency (Argus, ArisGlobal, Veeva Vault Safety), and any GxP findings.
We manage the offer, the counter scenario, and the resignation conversation. Most PV searches close in 14-28 days from kickoff.
Directional 2026 U.S. base salary estimates for venture-backed and mid-cap biotech and SaaS companies. Excludes equity, bonus, and sign-on. Confirm against current market data before extending offers.
| Role | Base Salary Range |
|---|---|
| Safety Specialist (Case Processing) | $95K–$135K |
| Senior Safety Scientist | $140K–$195K |
| Aggregate Report Author | $155K–$210K |
| Risk Management Plan Lead | $170K–$230K |
| Director of Pharmacovigilance | $230K–$310K |
| QPPV (EU or UK) | $260K–$360K |
| VP / Head of Drug Safety | $320K–$460K |
Sources: blended Radford, Mercer, and Recruits Lab placement data 2026. MD or PharmD premium on physician roles. Directional only.
Quick answers to the questions founders and hiring leaders ask most.
A pharmacovigilance recruiter sources, vets, and places drug safety professionals across case processing, signal detection, aggregate reporting, risk management, and QPPV leadership. Strong PV recruiters screen for direct ICH GVP, FAERS, and EudraVigilance experience, not just LinkedIn titles.
Industry average is 90-120 days for a Director of PV search at a clinical-stage biotech. Recruits Lab averages 14-28 days from kickoff to signed offer by maintaining warm relationships with the active U.S. and EU pool and screening on regulatory fluency before booking sponsor time.
A Senior Safety Scientist in 2026 typically earns $140K-$195K base in the U.S., with Aggregate Report Authors and Risk Management Plan Leads earning $155K-$230K. Director and VP of PV roles run $230K-$460K depending on commercial stage and whether an MD is required.
Build pharmacovigilance leadership 9-12 months before first product approval. Hiring after the FDA filing is too late to establish a defensible safety database, vendor model, and inspection readiness. Most launch delays attributable to PV are hiring timing failures.
Argus Safety, ArisGlobal LifeSphere Safety, and Veeva Vault Safety are the three dominant case management systems in 2026. Candidates should also have direct experience with FAERS, EudraVigilance EVDAS, MHRA Yellow Card, and PMDA reporting. Signal detection roles add Empirica Signal or Oracle Empirica fluency.
Yes. Pharmacovigilance is the regulated discipline. Drug Safety is the common organizational name in the U.S. industry. EU and UK companies use Pharmacovigilance. Job titles use both interchangeably.
BLA filed. Approval expected in 9 months. Sponsor had no internal PV leadership, an outsourced case processing vendor, and an FDA pre-approval inspection scheduled in 6 months. Needed a Director of Pharmacovigilance who could insource the function and own inspection readiness.
Recruits Lab built a 95-person target map from oncology PV teams at Bristol-Myers Squibb, Merck, AstraZeneca, and three mid-cap oncology biotechs. Screened on direct FDA inspection history and oncology safety experience. 6 finalists, 4 with oncology launch backgrounds.
Signed offer in 23 days from kickoff. Hire built a 5-person internal PV team, transitioned the CRO vendor, and led a clean FDA pre-approval inspection 5 months later with zero 483 observations.
"Recruits Lab was the only firm that could discuss GVP Module IX intelligently. Every other recruiter we tried sent us case processors and called them safety scientists."
"We needed an EU QPPV in 30 days. They had three qualified, residency-verified candidates in our pipeline within a week."
Yes. We work with both sponsor pharmacovigilance teams and CRO safety practices. The screening criteria and pool differ, and we run each search accordingly.
Yes. We maintain a verified pool of EU and UK Qualified Persons for Pharmacovigilance with residency, language, and 24/7 availability confirmed. Most are not publicly searchable.
Yes. We place Safety Physicians, Medical Reviewers, Drug Safety Physicians, and VP/Head of Drug Safety MD roles. Our physician pool sources from established sponsor safety organizations.
Every placement carries a 90-day replacement guarantee. We re-run the search at no fee. PV replacement is rare in our data because regulatory mis-hires usually surface during the structured interview process.
Yes. Pre-launch PV leadership searches are almost always confidential. We protect sponsor identity through the shortlist stage and only disclose on candidate finalist conversion.
Book a 30-minute pharmacovigilance hiring strategy review using the CTA on this page. We will scope the role, suggest a target list, and quote a subscription or contingency engagement.
Compensation data, hiring playbooks, case studies, and related recruiting specialties.
Four ways to engage. Pick whichever matches where you are.
30-minute strategy review with a senior recruiter. Free, no commitment.
Get startedTell us about the role. We respond with a calibration call within 24 hours.
Get startedSend a job description. We confirm fit and quote a subscription or contingency engagement.
Get startedSenior candidates: get represented to our active hiring pipeline.
Get startedRelated Resources
Hand-picked salary guides, market reports, and recruiter pages related to this topic. Authored by Darren Nelson and the Recruits Lab team.
Schedule a free 30-minute Hiring Strategy Review and walk away with a clear plan tailored to your roles.